Press Releases

Press Releases

Stay updated on the latest VistaGen News and get the details about important events, public financial reports, and our product pipeline updates.

SOUTH SAN FRANCISCO, CA / ACCESSWIRE / March 28, 2019 /  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other central nervous system (CNS) diseases and disorders with high unmet need,
SOUTH SAN FRANCISCO, CA / ACCESSWIRE / March 14, 2019 /  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, today announced that 
SOUTH SAN FRANCISCO, CA / ACCESSWIRE / March 13, 2019 /   VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, today announced that the
SOUTH SAN FRANCISCO, CA / ACCESSWIRE / March 7, 2019 /  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other central nervous system (CNS) diseases and disorders with high unmet need,
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, today announced the
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, today announced that
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, today announced
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2019 (GLOBE NEWSWIRE) --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, today announced
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc.  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for treating depression and other central nervous system (CNS) diseases and disorders with high unmet need,
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced that  Shawn Singh, Chief